Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy by Dunne, Victoria et al.
Inhibition of ataxia telangiectasia related-3 (ATR) improves
therapeutic index in preclinical models of non-small cell lung cancer
(NSCLC) radiotherapy
Dunne, V., Ghita, M., Small, D. M., Coffey, C. B. M., Weldon, S., Taggart, C. C., ... Butterworth, K. T. (2017).
Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small
cell lung cancer (NSCLC) radiotherapy. DOI: 10.1016/j.radonc.2017.06.025
Published in:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2017 Elsevier B.V.  This manuscript version is made available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/,which permits distribution and reproduction for noncommercial purposes, provided the
author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:09. Sep. 2018
                             Elsevier Editorial System(tm) for 
Radiotherapy and Oncology 
                                  Manuscript Draft 
 
 
Manuscript Number: RO-D-17-00439R2 
 
Title: Inhibition of ataxia telangectasia related-3 (ATR) improves 
therapeutic index in preclinical models of non-small cell lung cancer 
(NSCLC) radiotherapy  
 
Article Type: Full Length Article 
 
Keywords: ataxia telangiectasia related-3 (ATR); AZD6738; DNA damage 
response; non-small cell lung cancer (NSCLC); fibrosis, small animal 
radiotherapy research platform (SARRP). 
 
Corresponding Author: Dr Karl Butterworth, PhD 
 
Corresponding Author's Institution: Queens University Belfast 
 
First Author: Victoria  Dunne, BSc 
 
Order of Authors: Victoria  Dunne, BSc; Mihaela Ghita, PhD; Donna M 
Small, PhD; Caroline  C Coffey, PhD; Sinead Weldon , PhD; Clifford C 
Taggart, PhD; Sarah O Osman, PhD; Conor K McGarry, PhD; Kevin M Prise, 
PhD; Gerard G Hanna, PhD, FRCR; Karl T Butterworth, PhD 
 
Abstract: Background and purpose: To evaluate the impact of ATR 
inhibition using AZD6738 in combination with radiotherapy on the response 
of non-small cell lung cancer (NSCLC) tumour models and a murine model of 
radiation induced fibrosis.  
Materials and methods: AZD6738 was evaluated as a monotherapy and in 
combination with radiation in vitro and in vivo using A549 and H460 NSCLC 
models. Radiation induced pulmonary fibrosis was evaluated by cone beam 
computed tomography (CBCT) and histological staining. 
Results: AZD6738 specifically inhibits ATR kinase and enhanced 
radiobiological response in NSCLC models but not in human bronchial 
epithelial cells (HBECs) in vitro. Significant tumour growth delay was 
observed in cell line derived xenografts (CDXs) of H460 cells (p < 0.05) 
which were less significant in A549 cells. Combination of AZD6738 with 
radiotherapy showed no significant change in lung tissue density by CBCT 
(p > 0.5) and histological scoring of radiation induced fibrosis (p > 
0.5).  
Conclusion: Inhibition of ATR with AZD6738 in combination with 
radiotherapy improved tumour control without observable augmentation of 
late radiation induced toxicity further underpinning translation towards 






Karl Butterworth, PhD 
Centre for Cancer Research and Cell Biology 
Queen’s University Belfast 
T: 00 44 (0)2890 972307 
F: 00 44 (0)2890 972776 
E: k.butterworth@qub.ac.uk 
Prof Michael Baumann 
Editor-in-Chief 
Radiotherapy and Oncology Editorial Office,  
Heidelberg 
Germany  
         2
th
 June 2017 
Dear Sir, 
 
 I would like to submit the revised manuscript entitled ‘Inhibition of ataxia 
telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of 
non-small cell lung cancer (NSCLC) radiotherapy’ by Dunne et al. to be considered 
for publication as an original paper in Radiotherapy and Oncology. 
 
 The manuscript has been revised in line with the constructive criticisms of the 
reviewers. This has added to the quality and presentation, and we hope the article 
meets the required standards for publication in Radiotherapy and Oncology. 
 
I confirm that the author and co-authors currently have no papers that are 
under review or in press relevant to this publication.  
 







Karl Butterworth, PhD  
Assistant Professor in Translational Radiation Biology  
Centre for Cancer Research and Cell Biology 
Queen’s University Belfast 
Cover Letter
Radiotherapy and Oncology 
If you are submitting a revised manuscript, please also: 
a) outline each change made (point by point) as raised in the reviewer comments AND/OR b) provide 
a suitable rebuttal to each reviewer comment not addressed 
Response to Reviewers' comments: 
Reviewer #2: Please add p-values to table 1 (drug versus control, drug versus RT and RT+ drug 
versus RT alone) 
P values have been added for statistical comparison of different groups in table 1. 
*Point by Point detailed Response to Reviewer comments
Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in 
preclinical models of non-small cell lung cancer (NSCLC) radiotherapy 
Victoria Dunne BSc 
a
, Mihaela Ghita, PhD 
a
, Donna M Small PhD 
b
, Caroline B.M. Coffey 
PhD 
a
, Sinead Weldon PhD 
b
,  Clifford C Taggart PhD 
b
, Sarah Osman PhD 
c
, Conor K 
McGarry PhD 
c
, Kevin M. Prise PhD 
a
, Gerard G. Hanna PhD, FRCR 
a,c





 Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Northern Ireland, 
UK. 
b
 Centre for Experimental Medicine, Queen’s University Belfast, Northern Ireland, UK. 
c
 Northern Ireland Cancer Centre, Queen’s University Belfast, Northern Ireland, UK. 
 
* Corresponding author 
Centre for Cancer Research and Cell Biology 
Queen’s University Belfast 
97 Lisburn Road 
BT9 7AE 
Belfast 
Northern Ireland, UK 
Tel: 0044 2890 972307 




Running title: ATR inhibition improves therapeutic index in NSCLC models in vivo 
Keywords: ataxia telangiectasia related-3 (ATR), AZD6738, DNA damage response, non-




 ABSTRACT  
Background and purpose: To evaluate the impact of ATR inhibition using AZD6738 in 
combination with radiotherapy on the response of non-small cell lung cancer (NSCLC) 
tumour models and a murine model of radiation induced fibrosis.  
Materials and methods: AZD6738 was evaluated as a monotherapy and in combination with 
radiation in vitro and in vivo using A549 and H460 NSCLC models. Radiation induced 
pulmonary fibrosis was evaluated by cone beam computed tomography (CBCT) and 
histological staining. 
Results: AZD6738 specifically inhibits ATR kinase and enhanced radiobiological response in 
NSCLC models but not in human bronchial epithelial cells (HBECs) in vitro. Significant 
tumour growth delay was observed in cell line derived xenografts (CDXs) of H460 cells (p < 
0.05) which were less significant in A549 cells. Combination of AZD6738 with radiotherapy 
showed no significant change in lung tissue density by CBCT (p > 0.5) and histological 
scoring of radiation induced fibrosis (p > 0.5).  
Conclusion: Inhibition of ATR with AZD6738 in combination with radiotherapy increases 
mproved tumour growth delay control without observable augmentation of late radiation 




Lung cancer is the most frequently diagnosed cancer and leading cause of cancer mortality 
accounting for 1.8 million deaths annually (1). Radiotherapy has a major role in the 
management of non-small cell lung cancer (NSCLC), in particular the use of stereotactic 
ablative radiotherapy (SABR). SABR is now considered standard of care for inoperable 
patients with peripheral early-stage NSCLC (2) with 55.8% overall survival reported at 3 
years with high rates of local tumour control and moderate treatment-related morbidity (3). 
Despite these improvements, there remains an urgent need for the development of new 
therapies for NSCLC. 
Combining novel agents targeting the hallmarks of cancer and their biological response 
pathways has significant potential to improve the therapeutic index of radiotherapy (4–6). In 
particular, as the main biological effectiveness of radiotherapy results from DNA damage and 
considering the frequency of functional loss or dysregulation of key DNA damage response 
(DDR) proteins in tumours, agents directly targeting components of the DDR may hold 
significant therapeutic potential (7, 8).  
Ataxia telangiectasia mutated (ATM) and Rad3-related (ATR) are critical proteins which 
orchestrate the DDR, acting as apical kinases in response to DNA double strand breaks 
(DSBs) initially detected by damage sensing proteins such as MRN (MRE11-RAD50-NSB1) 
or PARP1 (poly(ADP-ribose) polymerase1). Both proteins belong to the phosphotidyl-
inositol 3-kinase related proteins (PIKK) family of serine/threonine kinases and crucially halt 
downstream effectors including cell cycle checkpoint kinases 1 (CHK1) and p53 causing cell 
cycle arrest at S and G2 checkpoints. ATM is the primary responder to DSBs whilst ATR is 
activated by a range of lesions including single strand DNA structures at resected ends of 
DBSs, strand cross links and after replication fork stalling (9–12). 
Over the past decade, a number of selective ATR inhibitors have been reported as tools in 
early studies to elucidate ATR pharmacology (10, 11, 13). Of these agents, AZD6738 has 
been developed as a highly potent, selective and bioavailable ATR inhibitor and evaluated as 
a monotherapy or in combination including radio- and chemotherapy (14, 15). Cumulatively, 
these data have supported the translation of AZD6738 and other ATR inhibitors to early 
phase clinical evaluation as a mono- and combination therapy with DNA damaging and 
molecular targeted agents (NCT02157792, NCT01955668, NCT02223923 and 
NCT02264678). 
Here, we evaluated AZD6738 as a monotherapy and in combination with multiple 
radiotherapy schedules in NSCLC models and a preclinical model of radiation induced 
fibrosis. Our data show significant tumour specific radiosensitization and tumour growth 
delay with no potentiation of radiation induced toxicity in a murine model of pulmonary 
underpinning future clinical evaluation in NSCLC. 
 
  
Materials and Methods 
Cell lines, drugs and reagents 
A549, H460 and human bronchial epithelial cells (HBECs) were purchased from the 
American type Culture collection (ATCC) and routinely tested for mycoplasma. Cell culture 
conditions are described in appendix A. 
AZD6738 was provided by AstraZeneca. For in vitro use, AZD6738 was dissolved in DMSO 
to a stock concentration of 10 mM and diluted in DMSO to the required working 
concentration. For in vivo use, AZD6738 was dissolved in DMSO at a concentration of 25 
mg/mL and diluted 1 in 5 with propylene glycol. An equal amount of water was added to 
yield 2.5 mg/mL in 10% DMSO, 40% propylene glycol and 50% sterile water. AZD6738 or 
drug vehicle was delivered by oral gavage at a concentration of 25 mg/kg for 28 days. 
Western blotting, clonogenic assay, DNA damage analysis and in vitro irradiation 
Protein analysis was performed by Western blotting (Appendix A). Clonogenic assay was 
performed using the protocol of Markus and Puck (16). DNA damage analysis was performed 
by quantification of DSBs using immuno-cytochemical staining of 53BP1 (Appendix A). All 
cells were irradiated with 225 kVp X-rays using an X-Rad 225 generator (Precision X-ray 
Inc., North Bradford, CT) with a 2 mm copper filter at a dose rate of 0.57 Gy min
-1
. 
Animals and maintenance 
Tumour response studies were performed by establishing A549 and H460 cell line derived 
xenografts (CDXs, Appendix A) in 8-10 week old female SCID mice obtained from Charles 
River Laboratories (Oxford, UK).  
Radiation induced toxicity was investigated in fibrosis prone C57BL/6J mice at 8-10 weeks 
old obtained from Charles River Laboratories (Oxford, UK). All experimental procedures 
were performed in accordance with UK Home Office approved protocols for in vivo 
experimentation. For all in vivo studies a minimum of 7 animals per group were used. 
Preclinical study design 
A schematic overview of the study design is shown in Figure 2. Tumour response was 
evaluated in A549 and H460 CDXs and volumes calculated from calliper measurements 
using the modified ellipsoidal formula ((17), Appendix 1). AZD6738 was administered 1 
hour prior to irradiation. Mice were irradiated with a total dose of 12 Gy delivered as a single 
fraction or as three daily fractions of 4 Gy. Treatment plans were generated to give 100% 
tumour coverage using a parallel opposed beam geometry with a 10 x 10 mm collimator at a 
dose rate of 2.8 ± 0.12 Gy/min. Mice were removed from the study at a maximum tumour 
volume of 600-800 mm
3
. 
Radiation induced pulmonary fibrosis was induced by delivering a total dose of 20 Gy as a 
single fraction or as three daily fractions of 6.67 Gy/day across consecutive days. A parallel 
opposed beam geometry with a 5 x 5 mm collimator (dose rate 0.27 ± 0.16 Gy/min) was used 
to target an isocentre in the upper left lung for minimal displacement during breathing and to 
spare organs at risk.  
CBCT imaging and analysis 
Lung tissue density was monitored using on board CBCT imaging on SARRP. Images were 
acquired at 50 kVp before and at 4, 12 and 26 weeks after irradiation. Non-irradiated control 
animals were imaged at the same time intervals. Quantitative CBCT data was extracted from 
the scans by outlining the whole of the irradiated lung using 3D Slicer 4.0 (www.slicer.org). 
Further details are given in Appendix A. 
Histological assessment of radiation induced fibrosis 
Lung tissues were fixed by inter-tracheal infusion with 4% formaldehyde and processed for 
histological evaluation detailed in Appendix A. 
Data fitting and statistical analysis 
Details of statistical analysis are given in Appendix A. 
  
RESULTS 
AZD6738 inhibits ATR kinase and radiosensitizes NSCLC models but not human 
bronchial epithelial cells in vitro 
The effect of AZD6738 as a single agent and in combination with radiotherapy was 
investigated in A549 and H460 NSCLC cells and HBECs. From Figure 1 (Panel A), at the 
protein level, both A549 and H460 cells show high endogenous expression of ATR which is 
selectively inhibited by AZD6738 at concentrations of 250 nM in A459 cells and 100 nM in 
H460 and HBEC cells following 2 hours treatment. Both tumour models showed high 
expression of ATR following exposure to 2 Gy which decreased with AZD6738 treatment. In 
comparison, HBEC cells have low endogenous levels of ATR which was induced in response 
to radiation exposure and increased with 100 nM AZD6738. 
The effect of AZD6738 on cell survival was determined from un-irradiated, drug treated 
control samples which showed significant (p < 0.05) decreases compared to vehicle treated 
controls of 33.4%, 41.1% and 16.4% in A549, H460 and HBEC cells respectively. In 
combination with radiation, AZD6738 increased the radiosensitivity of A549 and H460 but 
not HBECs. In A549 cells, a significant radiosensitizing effect was observed only at 8 Gy at a 
concentration of 250 nM (p = 0.07). In comparison, at a concentration of 100 nM, H460 cells 
showed significant radiosensitization at all doses (p < 0.038). Dose enhancement factors were 
calculated as 1.03 and 1.5 in A549 and H460 cells respectively. No significant effects on the 
radiobiological response of HBECs were observed (p > 0.5), supporting the underlying 
tumour specificity of AZD6738. 
At the DNA damage level, AZD6738 significantly increased 53BP1 foci in A549 (p < 0.01) 
but not in H460 cells (p > 0.5). When combined with radiation, A549 cells showed 
significantly increased foci numbers at 4 hours (p = 0.03). H460 cells showed a significant 
increase in DSB induction at 2 hours (p < 0.01) which remained elevated at 4 and 8 hours (p 
< 0.03). In both cell lines elevated levels of DNA damage in AZD6738 treated cells had been 
resolved by 24 hours (p > 0.5). HBECs showed an elevated level of foci when treated as a 
single agent (p = 0.04) with no significant increase in combination with radiation at each time 
point investigated (p > 0.5). 
AZD6738 with radiotherapy causes significant tumour growth delay in vivo 
AZD6738 as a single agent and in combination with radiotherapy was investigated in CDX 
bearing mice treatedand the effects on tumour growth delay parameters for each of the 
experimental groups summarised in table 1.. 25 mg/kg of AZD6738 was selected as a known 
well tolerated dose (AstraZeneca personal communication, (14)). 12 Gy was selected based 
on the radiobiological response parameters of the cell models (A549, α = 0.39 ± 0.03, β = 
0.01 ± 0.01; H460, α = 0.12 ± 0.05, β = 0.05 ± 0.01). BED values for single fraction 
exposures in A549 and H460 cells were 15.7 Gy and 72 Gy respectively. For fractionated 
exposures this was calculated to be 13.2 Gy and 32 Gy in A549 and H460 cells respectively. 
A549 tumours treated with AZD6738 showed no significant tumour growth delay compared 
to vehicle treated control animals (p < 0.5). Both single fraction and fractionated animals 
showed significant tumour growth delay compared to control animals (p < 0.01) from day 20 
with an approximate doubling of tumour volume over the 80 days of the experiment. When 
combined with AZD6738, tumour growth was further delayed for approximately 4 and 10 
days for single fraction and fractionated exposures respectively (p < 0.03). In comparison, 
H460 tumours treated with AZD6738 as a single agent showed significant tumour growth 
delay compared to vehicle treated control animals (p = 0.04) with a quadrupling time , 
reaching a volume ofto 400 mm
3
 in of 19 days. Irradiated animals showed significant tumour 
growth delay compared to all non-irradiated treated animals, with a further delay of 20 and 23 
days to reach a volume of 400 mm
3
 . (p < 0.002 ). When combined with AZD6738, tumour 
growth was further delayed for approximately 24 and 23 days with single fraction and 
fractionated exposures respectively (p < 0.04). AZD6738 was well tolerated in all animals 
with transient weight loss of less than 10% observed immediately following radiotherapy. 
AZD6738 with radiotherapy does not cause significant changes in lung tissue density 
and radiation induced pulmonary fibrosis 
Lung tissue density changes were determined by CBCT imaging on SARRP. As a single 
agent, AZD6738 showed no significant increase in average lung CT number over 26 weeks 
compared to drug vehicle treated animals (Appendix A, p > 0.5). Using an α/β value of 2.5 
for mouse lung (18, 19), the BEDs for single fraction and fractionated deliveries were 180 
and 73.4 Gy respectively. 
All animals exposed to single fraction and fractionated radiotherapy showed tissue density 
increases as a function of time reaching a maximum at 26 week ((p < 0.01, Figure 4). 
Changes in lung density were localised to the irradiated region for all groups and time points. 
CT numbers of approximately 500 ± 44.2 at week 0 in all experimental groups increased to 
750 ± 54.1 and 780 ± 60.2 for single fraction and fractionated exposures respectively. No 
significant changes were detected between irradiated animals and those receiving drug 
vehicle or combination treatment with AZD6738 (p > 0.5). 
Tissue sections were scored using the modified Ashcroft scale (20) for pulmonary fibrosis. 
Histological evaluation of control lungs at week 0 and un-irradiated lungs at each time point 
showed normal lung architecture with no fibrotic burden. 
Mice irradiated with a 20 Gy single fraction in combination with drug vehicle (Figure 5, 
panel A) or with AZD6738 (Figure 5, panel C) showed equal increases in fibrosis score at 26 
weeks to less than 2 compared to week 4 (p < 0.001). Sections showed clear fibrotic changes 
with unconnected knot like formations, partially enlarged alveoli with around a 3 fold 
increase in septal thickening. For fractionated exposures with drug vehicle (Figure 5, panel 
B) and AZD6738 (Figure 5, panel D), much smaller changes in fibrotic index were observed 
with values < 0.5 at 26 weeks (p < 0.1). 
  
Discussion 
ATR is a promising target in cancer treatment for which several small inhibitors have been 
developed and shown efficacy in combination with radiotherapy (10, 11, 15, 21–25). In this 
study, AZD6738 was evaluated as a monotherapy or in combination with radiotherapy in 
NSCLC tumour models, and in a radiation induced fibrosis model of normal tissue 
complication. To our knowledge this is the first systematic evaluation of ATR inhibition to 
simultaneously interrogate tumour and normal tissue response across multiple radiotherapy 
dosing schedules using small animal image guided radiotherapy. 
Our data show AZD6738 to be a highly selective and potent inhibitor of ATR causing dose 
dependent radiosensitization in A459 and H460 but not HBEC cells in vitro. Using CDXs, 
AZD6738 was shown to have more pronounced effects on H460 cells compared to A549 
cells which showed lower levels of tumour growth over the same time period. These findings 
are in close agreement with those of previous reports demonstrating AZD6738 as a potent 
sensitizer to cisplatin, gemcitabine (14) and radiation (15). We propose that the observed 
radiosensitization in our study is due to abrogation of the radiation induced G2 cell cycle 
checkpoint and inhibition of homologous recombination (15). The differential effects in A549 
and H460 cells agree with observations of Vendetti et al, and may similarly be due to the 
predominance of apoptosis in H460 cells rather than senescence in A549 cells (14). 
Furthermore, differences in tumour growth delay agreed with BED calculations validating the 
empirical dose fractionation hypothesis in our experimental models. 
Our data further provide a strong rationale for targeting ATR inhibitors due to its deleterious 
effect on cancer cells harbouring defects in homologous recombination which could 
potentially enhance the effectiveness of DNA damaging agents including radiotherapy. 
However, a major concern in combination therapy is normal tissue complication. Inhibition 
of ATR could potentially impact normal tissue as ATR is an essential protein that regulates 
the firing at origins of replication during S phase and has been shown to be embryonically 
lethal in mice (26). Additionally, ATR inhibition may prevent replication and increase breaks 
at fragile sites in the DNA of normal cells which may be especially prone to breakage after 
DNA damaging treatment in combination with an inhibitor and may impact ATM function 
through direct interactions. Our data showed high tumour specificity of AZD6738 with no 
significant effects on the radiobiological response of HBEC cells in vitro and on lung tissue 
density and fibrosis in C56BL6 mice using the dosing regimens investigated. We hypothesis 
that these effects may be due to differences in the fidelity of HR mediated repair and P53 
status.  
CBCT analysis detected comparable changes at matched time points across all groups yet 
these changes did not correlate with fibrosis scores for animals treated with fractionated 
radiotherapy. For lung tissue, animal studies of late effects have an established α/β ratio of 
approximately 2-3 Gy (18, 19). Our data may therefore be attributed to differences in the 
BED which was approximately 2.5 times greater for single fraction exposures. Additionally, 
although C57BL6 are a known fibrosis prone strain, application of the model is confounded 
by the late response being dominated by large accumulation of pleural fluid detected 
following whole thorax irradiation with 15 Gy (28). Our data indicate a lack of fibrosis 
following fractionated schedules with the observed increase in tissue density being attributed 
to pleural effusion. The observed increase in CT numbers at 26 weeks is comparable to the 
trends previously reported for partial lung irradiation at the same dose (29). Although the in 
vivo toxicity profile and long term effects AZD6738 remain to be determined in the clinical 
setting, as conditional reduction of ATR expression to 10% of normal levels in adult mice has 
been shown to minimal impact on normal tissue homeostasis (30). 
Our experimental approach may be improved with analysis of additional endpoints including 
early effects such as pneumonitis, functional assessment of radiation induced lung pathology 
and improvements in preclinical radiotherapy procedures such as beam gating or forced 
breath hold to more accurately model clinical developments (31–33). Further investigation in 
specific patient subgroups with known driver mutations associated with NSCLC including 
EGFR, MET, BRAF, and TP53 (34) should also be explore for clinical translation along with 
the identification of biomarkers to select patients most likely to benefit from the novel 
treatment combination (35). 
Conclusions 
This work demonstrates the therapeutic advantage of combining AZD6738 with radiotherapy 
in the treatment of NSCLC by improving increasing tumour growthcontrol delay with no 
significant increase in radiation induced toxicity. These data provide further support for 
AZD6738 in combination with radiotherapy to be explored in early phase clinical evaluation. 
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Figure legends 
Fig. 1. Impact of AZD6738 on ATR protein levels and radiobiological response of A549 and 
H460 non-small cell lung cancer (NSCLC) and human bronchial epithelial cells in vitro. (A) 
Protein analysis of total ATR and total AKT by Western blotting for cells treated with 100 
nM AZD6738 in combination with 2 Gy; (B) Radiation dose response curves for cells treated 
with 100 nM AZD6738 in combination radiation; (C) DNA damage induction and repair at 
time intervals up to 24 hrs following irradiation by scoring of double strand breaks (DSBs) 
using immuno-histochemical staining of 53BP1. Probability values were classified as *** (p 
< 0. 005), ** (p < 0. 05) and * (p < 0.1). 
Fig. 2. Schematic overview of the preclinical study design. All mice received AZD6738 (25 
mg/kg delivered by oral gavage once per day, p.o.q.d) prior to radiotherapy. Tumour response 
studies were initiated in mice bearing cell line derived xenografts (CDXs) at a volume of 100 
mm
3
 and irradiated with a total dose of 12 Gy delivered as a single fraction or three daily 
fractions of 4 Gy. Radiation induced fibrosis was evaluated by irradiated a 5 x 5 mm sub-
volume of the upper right lung with a total dose of 20 Gy delivered as a single fraction or 
three daily fractions of 6.67 Gy.   
Fig. 3. Impact of AZD6738 on cell lines derived xenografts (CDXs) of A549 (panels A and 
B) and H460 (panels C and D) cells following single fraction (panels A and C) and 
fractionated radiotherapy exposures (panels B and D). In all panels mice were treated with 
either drug vehicle (■); AZD6738 (25 mg/kg per day for 28 days (▼); radiotherapy (●); 
radiotherapy in combination with AZD6738 (▲). Data is presented as median tumour 
volume for the experimental group ± standard error.   
  
Fig. 4. Quantitative analysis of lung tissue density changes measured by cone beam 
computed tomography (CBCT) longitudinally for 26 weeks after irradiation. Mice were 
irradiated with a total dose of 20 Gy single fraction in combination with drug vehicle (Panel 
A) or AZD6738 (25 mg/kg per day, Panel C), and with three fractions of 6.67 Gy in 
combination with drug vehicle (Panel B) or AZD6738 (Panel D). Data is presented as the 
difference between the average CT number of the irradiated lung and the average CT number 
in air. Data is presented as raw numbers at all time-points. Probability values were classified 
as *** (p < 0. 005), ** (p < 0. 05) and * (p < 0.1). 
  
Fig. 5. Histological staining and quantification of radiation induced pulmonary fibrosis. 
Stained lungs were electronically scanned and five images scored from the upper region of 
the left lobe. Pulmonary fibrosis was scored using the modified Ashcroft scale (0-8) at 10 x 
magnification by independent and blind observers. Mice were irradiated with a total dose of 
20 Gy single fraction in combination with drug vehicle (Panel A) or with AZD6738 (25 
mg/kg per day, Panel C), and with three fractions of 6.67 Gy in combination with drug 
vehicle (Panel B) or with AZD6738 (Panel D). Data is presented as the fibrosis score ± SEM. 
A representative image from each of the experimental groups is inset in each panel. 
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 ABSTRACT  
Background and purpose: To evaluate the impact of ATR inhibition using AZD6738 in 
combination with radiotherapy on the response of non-small cell lung cancer (NSCLC) 
tumour models and a murine model of radiation induced fibrosis.  
Materials and methods: AZD6738 was evaluated as a monotherapy and in combination with 
radiation in vitro and in vivo using A549 and H460 NSCLC models. Radiation induced 
pulmonary fibrosis was evaluated by cone beam computed tomography (CBCT) and 
histological staining. 
Results: AZD6738 specifically inhibits ATR kinase and enhanced radiobiological response in 
NSCLC models but not in human bronchial epithelial cells (HBECs) in vitro. Significant 
tumour growth delay was observed in cell line derived xenografts (CDXs) of H460 cells (p < 
0.05) which were less significant in A549 cells. Combination of AZD6738 with radiotherapy 
showed no significant change in lung tissue density by CBCT (p > 0.5) and histological 
scoring of radiation induced fibrosis (p > 0.5).  
Conclusion: Inhibition of ATR with AZD6738 in combination with radiotherapy increases 
tumour growth delay without observable augmentation of late radiation induced toxicity 




Lung cancer is the most frequently diagnosed cancer and leading cause of cancer mortality 
accounting for 1.8 million deaths annually (1). Radiotherapy has a major role in the 
management of non-small cell lung cancer (NSCLC), in particular the use of stereotactic 
ablative radiotherapy (SABR). SABR is now considered standard of care for inoperable 
patients with peripheral early-stage NSCLC (2) with 55.8% overall survival reported at 3 
years with high rates of local tumour control and moderate treatment-related morbidity (3). 
Despite these improvements, there remains an urgent need for the development of new 
therapies for NSCLC. 
Combining novel agents targeting the hallmarks of cancer and their biological response 
pathways has significant potential to improve the therapeutic index of radiotherapy (4–6). In 
particular, as the main biological effectiveness of radiotherapy results from DNA damage and 
considering the frequency of functional loss or dysregulation of key DNA damage response 
(DDR) proteins in tumours, agents directly targeting components of the DDR may hold 
significant therapeutic potential (7, 8).  
Ataxia telangiectasia mutated (ATM) and Rad3-related (ATR) are critical proteins which 
orchestrate the DDR, acting as apical kinases in response to DNA double strand breaks 
(DSBs) initially detected by damage sensing proteins such as MRN (MRE11-RAD50-NSB1) 
or PARP1 (poly(ADP-ribose) polymerase1). Both proteins belong to the phosphotidyl-
inositol 3-kinase related proteins (PIKK) family of serine/threonine kinases and crucially halt 
downstream effectors including cell cycle checkpoint kinases 1 (CHK1) and p53 causing cell 
cycle arrest at S and G2 checkpoints. ATM is the primary responder to DSBs whilst ATR is 
activated by a range of lesions including single strand DNA structures at resected ends of 
DBSs, strand cross links and after replication fork stalling (9–12). 
Over the past decade, a number of selective ATR inhibitors have been reported as tools in 
early studies to elucidate ATR pharmacology (10, 11, 13). Of these agents, AZD6738 has 
been developed as a highly potent, selective and bioavailable ATR inhibitor and evaluated as 
a monotherapy or in combination including radio- and chemotherapy (14, 15). Cumulatively, 
these data have supported the translation of AZD6738 and other ATR inhibitors to early 
phase clinical evaluation as a mono- and combination therapy with DNA damaging and 
molecular targeted agents (NCT02157792, NCT01955668, NCT02223923 and 
NCT02264678). 
Here, we evaluated AZD6738 as a monotherapy and in combination with multiple 
radiotherapy schedules in NSCLC models and a preclinical model of radiation induced 
fibrosis. Our data show significant tumour specific radiosensitization and tumour growth 
delay with no potentiation of radiation induced toxicity in a murine model of pulmonary 
underpinning future clinical evaluation in NSCLC. 
 
  
Materials and Methods 
Cell lines, drugs and reagents 
A549, H460 and human bronchial epithelial cells (HBECs) were purchased from the 
American type Culture collection (ATCC) and routinely tested for mycoplasma. Cell culture 
conditions are described in appendix A. 
AZD6738 was provided by AstraZeneca. For in vitro use, AZD6738 was dissolved in DMSO 
to a stock concentration of 10 mM and diluted in DMSO to the required working 
concentration. For in vivo use, AZD6738 was dissolved in DMSO at a concentration of 25 
mg/mL and diluted 1 in 5 with propylene glycol. An equal amount of water was added to 
yield 2.5 mg/mL in 10% DMSO, 40% propylene glycol and 50% sterile water. AZD6738 or 
drug vehicle was delivered by oral gavage at a concentration of 25 mg/kg for 28 days. 
Western blotting, clonogenic assay, DNA damage analysis and in vitro irradiation 
Protein analysis was performed by Western blotting (Appendix A). Clonogenic assay was 
performed using the protocol of Markus and Puck (16). DNA damage analysis was performed 
by quantification of DSBs using immuno-cytochemical staining of 53BP1 (Appendix A). All 
cells were irradiated with 225 kVp X-rays using an X-Rad 225 generator (Precision X-ray 
Inc., North Bradford, CT) with a 2 mm copper filter at a dose rate of 0.57 Gy min
-1
. 
Animals and maintenance 
Tumour response studies were performed by establishing A549 and H460 cell line derived 
xenografts (CDXs, Appendix A) in 8-10 week old female SCID mice obtained from Charles 
River Laboratories (Oxford, UK).  
Radiation induced toxicity was investigated in fibrosis prone C57BL/6J mice at 8-10 weeks 
old obtained from Charles River Laboratories (Oxford, UK). All experimental procedures 
were performed in accordance with UK Home Office approved protocols for in vivo 
experimentation. For all in vivo studies a minimum of 7 animals per group were used. 
Preclinical study design 
A schematic overview of the study design is shown in Figure 2. Tumour response was 
evaluated in A549 and H460 CDXs and volumes calculated from calliper measurements 
using the modified ellipsoidal formula ((17), Appendix 1). AZD6738 was administered 1 
hour prior to irradiation. Mice were irradiated with a total dose of 12 Gy delivered as a single 
fraction or as three daily fractions of 4 Gy. Treatment plans were generated to give 100% 
tumour coverage using a parallel opposed beam geometry with a 10 x 10 mm collimator at a 
dose rate of 2.8 ± 0.12 Gy/min. Mice were removed from the study at a maximum tumour 
volume of 600-800 mm
3
. 
Radiation induced pulmonary fibrosis was induced by delivering a total dose of 20 Gy as a 
single fraction or as three daily fractions of 6.67 Gy/day across consecutive days. A parallel 
opposed beam geometry with a 5 x 5 mm collimator (dose rate 0.27 ± 0.16 Gy/min) was used 
to target an isocentre in the upper left lung for minimal displacement during breathing and to 
spare organs at risk.  
CBCT imaging and analysis 
Lung tissue density was monitored using on board CBCT imaging on SARRP. Images were 
acquired at 50 kVp before and at 4, 12 and 26 weeks after irradiation. Non-irradiated control 
animals were imaged at the same time intervals. Quantitative CBCT data was extracted from 
the scans by outlining the whole of the irradiated lung using 3D Slicer 4.0 (www.slicer.org). 
Further details are given in Appendix A. 
Histological assessment of radiation induced fibrosis 
Lung tissues were fixed by inter-tracheal infusion with 4% formaldehyde and processed for 
histological evaluation detailed in Appendix A. 
Data fitting and statistical analysis 
Details of statistical analysis are given in Appendix A. 
  
RESULTS 
AZD6738 inhibits ATR kinase and radiosensitizes NSCLC models but not human 
bronchial epithelial cells in vitro 
The effect of AZD6738 as a single agent and in combination with radiotherapy was 
investigated in A549 and H460 NSCLC cells and HBECs. From Figure 1 (Panel A), at the 
protein level, both A549 and H460 cells show high endogenous expression of ATR which is 
selectively inhibited by AZD6738 at concentrations of 250 nM in A459 cells and 100 nM in 
H460 and HBEC cells following 2 hours treatment. Both tumour models showed high 
expression of ATR following exposure to 2 Gy which decreased with AZD6738 treatment. In 
comparison, HBEC cells have low endogenous levels of ATR which was induced in response 
to radiation exposure and increased with 100 nM AZD6738. 
The effect of AZD6738 on cell survival was determined from un-irradiated, drug treated 
control samples which showed significant (p < 0.05) decreases compared to vehicle treated 
controls of 33.4%, 41.1% and 16.4% in A549, H460 and HBEC cells respectively. In 
combination with radiation, AZD6738 increased the radiosensitivity of A549 and H460 but 
not HBECs. In A549 cells, a significant radiosensitizing effect was observed only at 8 Gy at a 
concentration of 250 nM (p = 0.07). In comparison, at a concentration of 100 nM, H460 cells 
showed significant radiosensitization at all doses (p < 0.038). Dose enhancement factors were 
calculated as 1.03 and 1.5 in A549 and H460 cells respectively. No significant effects on the 
radiobiological response of HBECs were observed (p > 0.5), supporting the underlying 
tumour specificity of AZD6738. 
At the DNA damage level, AZD6738 significantly increased 53BP1 foci in A549 (p < 0.01) 
but not in H460 cells (p > 0.5). When combined with radiation, A549 cells showed 
significantly increased foci numbers at 4 hours (p = 0.03). H460 cells showed a significant 
increase in DSB induction at 2 hours (p < 0.01) which remained elevated at 4 and 8 hours (p 
< 0.03). In both cell lines elevated levels of DNA damage in AZD6738 treated cells had been 
resolved by 24 hours (p > 0.5). HBECs showed an elevated level of foci when treated as a 
single agent (p = 0.04) with no significant increase in combination with radiation at each time 
point investigated (p > 0.5). 
AZD6738 with radiotherapy causes significant tumour growth delay in vivo 
AZD6738 as a single agent and in combination with radiotherapy was investigated in CDX 
bearing mice and the effects on tumour growth delay parameters for each of the experimental 
groups summarised in table 1.25 mg/kg of AZD6738 was selected as a known well tolerated 
dose (AstraZeneca personal communication, (14)). 12 Gy was selected based on the 
radiobiological response parameters of the cell models (A549, α = 0.39 ± 0.03, β = 0.01 ± 
0.01; H460, α = 0.12 ± 0.05, β = 0.05 ± 0.01). BED values for single fraction exposures in 
A549 and H460 cells were 15.7 Gy and 72 Gy respectively. For fractionated exposures this 
was calculated to be 13.2 Gy and 32 Gy in A549 and H460 cells respectively. 
A549 tumours treated with AZD6738 showed no significant tumour growth delay compared 
to vehicle treated control animals (p < 0.5). Both single fraction and fractionated animals 
showed significant tumour growth delay compared to control animals (p <0.01) from day 20 
with an approximate doubling of tumour volume over the 80 days of the experiment. When 
combined with AZD6738, tumour growth was further delayed for approximately 4 and 10 
days for single fraction and fractionated exposures respectively (p <0.03). In comparison, 
H460 tumours treated with AZD6738 as a single agent showed significant tumour growth 
delay compared to vehicle treated control animals (p = 0.04) with a quadrupling time to 400 
mm
3
 of 19 days. Irradiated animals showed significant tumour growth delay compared to all 
non-irradiated treated animals, with a further delay of 20 and 23 days to reach a volume of 
400 mm
3
 (p<0.002 ). When combined with AZD6738, tumour growth was further delayed for 
approximately 24 and 23 days with single fraction and fractionated exposures respectively 
(p<0.04). AZD6738 was well tolerated in all animals with transient weight loss of less than 
10% observed immediately following radiotherapy. 
AZD6738 with radiotherapy does not cause significant changes in lung tissue density 
and radiation induced pulmonary fibrosis 
Lung tissue density changes were determined by CBCT imaging on SARRP. As a single 
agent, AZD6738 showed no significant increase in average lung CT number over 26 weeks 
compared to drug vehicle treated animals (Appendix A, p > 0.5). Using an α/β value of 2.5 
for mouse lung (18, 19), the BEDs for single fraction and fractionated deliveries were 180 
and 73.4 Gy respectively. 
All animals exposed to single fraction and fractionated radiotherapy showed tissue density 
increases as a function of time reaching a maximum at 26 week ((p < 0.01, Figure 4). 
Changes in lung density were localised to the irradiated region for all groups and time points. 
CT numbers of approximately 500 ± 44.2 at week 0 in all experimental groups increased to 
750 ± 54.1 and 780 ± 60.2 for single fraction and fractionated exposures respectively. No 
significant changes were detected between irradiated animals and those receiving drug 
vehicle or combination treatment with AZD6738 (p > 0.5). 
Tissue sections were scored using the modified Ashcroft scale (20) for pulmonary fibrosis. 
Histological evaluation of control lungs at week 0 and un-irradiated lungs at each time point 
showed normal lung architecture with no fibrotic burden. 
Mice irradiated with a 20 Gy single fraction in combination with drug vehicle (Figure 5, 
panel A) or with AZD6738 (Figure 5, panel C) showed equal increases in fibrosis score at 26 
weeks to less than 2 compared to week 4 (p < 0.001). Sections showed clear fibrotic changes 
with unconnected knot like formations, partially enlarged alveoli with around a 3 fold 
increase in septal thickening. For fractionated exposures with drug vehicle (Figure 5, panel 
B) and AZD6738 (Figure 5, panel D), much smaller changes in fibrotic index were observed 
with values < 0.5 at 26 weeks (p < 0.1). 
  
Discussion 
ATR is a promising target in cancer treatment for which several inhibitors have shown 
efficacy in combination with radiotherapy (10, 11, 15, 21–25). In this study, AZD6738 was 
evaluated as a monotherapy or in combination with radiotherapy in NSCLC tumour models, 
and in a radiation induced fibrosis model of normal tissue complication. To our knowledge 
this is the first systematic evaluation of ATR inhibition to simultaneously interrogate tumour 
and normal tissue response across multiple radiotherapy dosing schedules using small animal 
image guided radiotherapy. 
Our data show AZD6738 to be a highly selective and potent inhibitor of ATR causing dose 
dependent radiosensitization in A459 and H460 but not HBEC cells in vitro. Using CDXs, 
AZD6738 was shown to have more pronounced effects on H460 cells compared to A549 
cells which showed lower levels of tumour growth over the same time period. These findings 
are in close agreement with those of previous reports demonstrating AZD6738 as a potent 
sensitizer to cisplatin, gemcitabine (14) and radiation (15). We propose that the observed 
radiosensitization in our study is due to abrogation of the radiation induced G2 cell cycle 
checkpoint and inhibition of homologous recombination (15). The differential effects in A549 
and H460 cells agree with observations of Vendetti et al, and may similarly be due to the 
predominance of apoptosis in H460 cells rather than senescence in A549 cells (14). 
Furthermore, differences in tumour growth delay agreed with BED calculations validating the 
empirical dose fractionation hypothesis in our experimental models. 
Our data further provide a strong rationale for targeting ATR inhibitors due to its deleterious 
effect on cancer cells harbouring defects in homologous recombination which could 
potentially enhance the effectiveness of DNA damaging agents including radiotherapy. 
However, a major concern in combination therapy is normal tissue complication. Inhibition 
of ATR could potentially impact normal tissue as ATR is an essential protein that regulates 
the firing at origins of replication during S phase and has been shown to be embryonically 
lethal in mice (26). Additionally, ATR inhibition may prevent replication and increase breaks 
at fragile sites in the DNA of normal cells which may be especially prone to breakage after 
DNA damaging treatment in combination with an inhibitor and may impact ATM function 
through direct interactions. Our data showed high tumour specificity of AZD6738 with no 
significant effects on the radiobiological response of HBEC cells in vitro and on lung tissue 
density and fibrosis in C56BL6 mice using the dosing regimens investigated. We hypothesis 
that these effects may be due to differences in the fidelity of HR mediated repair including 
P53 status.  
CBCT analysis detected comparable changes at matched time points across all groups yet 
these changes did not correlate with fibrosis scores for animals treated with fractionated 
radiotherapy. For lung tissue, animal studies of late effects have an established α/β ratio of 
approximately 2-3 Gy (18, 19). Our data may therefore be attributed to differences in the 
BED which was approximately 2.5 times greater for single fraction exposures. Additionally, 
although C57BL6 are a known fibrosis prone strain, application of the model is confounded 
by the late response being dominated by large accumulation of pleural fluid detected 
following whole thorax irradiation with 15 Gy (28). Our data indicate a lack of fibrosis 
following fractionated schedules with the observed increase in tissue density being attributed 
to pleural effusion. The observed increase in CT numbers at 26 weeks is comparable to the 
trends previously reported for partial lung irradiation at the same dose (29). Although the in 
vivo toxicity profile and long term effects AZD6738 remain to be determined in the clinical 
setting as conditional reduction of ATR expression to 10% of normal levels in adult mice has 
been shown to minimal impact on normal tissue homeostasis (30). 
Our experimental approach may be improved with analysis of additional endpoints including 
early effects such as pneumonitis, functional assessment of radiation induced lung pathology 
and improvements in preclinical radiotherapy procedures such as beam gating or forced 
breath hold to more accurately model clinical developments (31–33). Further investigation in 
specific patient subgroups with known driver mutations associated with NSCLC including 
EGFR, MET, BRAF, and TP53 (34) should also be explore for clinical translation along with 
the identification of biomarkers to select patients most likely to benefit from the novel 
treatment combination (35). 
Conclusions 
This work demonstrates the therapeutic advantage of combining AZD6738 with radiotherapy 
in the treatment of NSCLC by increasing tumour growth delay with no significant increase in 
radiation induced toxicity. These data provide further support for AZD6738 in combination 
with radiotherapy to be explored in early phase clinical evaluation. 
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Figure legends 
Fig. 1. Impact of AZD6738 on ATR protein levels and radiobiological response of A549 and 
H460 non-small cell lung cancer (NSCLC) and human bronchial epithelial cells in vitro. (A) 
Protein analysis of total ATR and total AKT by Western blotting for cells treated with 100 
nM AZD6738 in combination with 2 Gy; (B) Radiation dose response curves for cells treated 
with 100 nM AZD6738 in combination radiation; (C) DNA damage induction and repair at 
time intervals up to 24 hrs following irradiation by scoring of double strand breaks (DSBs) 
using immuno-histochemical staining of 53BP1. Probability values were classified as *** (p 
< 0. 005), ** (p < 0. 05) and * (p < 0.1). 
Fig. 2. Schematic overview of the preclinical study design. All mice received AZD6738 (25 
mg/kg delivered by oral gavage once per day, p.o.q.d) prior to radiotherapy. Tumour response 
studies were initiated in mice bearing cell line derived xenografts (CDXs) at a volume of 100 
mm
3
 and irradiated with a total dose of 12 Gy delivered as a single fraction or three daily 
fractions of 4 Gy. Radiation induced fibrosis was evaluated by irradiated a 5 x 5 mm sub-
volume of the upper right lung with a total dose of 20 Gy delivered as a single fraction or 
three daily fractions of 6.67 Gy.   
Fig. 3. Impact of AZD6738 on cell lines derived xenografts (CDXs) of A549 (panels A and 
B) and H460 (panels C and D) cells following single fraction (panels A and C) and 
fractionated radiotherapy exposures (panels B and D). In all panels mice were treated with 
either drug vehicle (■); AZD6738 (25 mg/kg per day for 28 days (▼); radiotherapy (●); 
radiotherapy in combination with AZD6738 (▲). Data is presented as median tumour 
volume for the experimental group ± standard error.   
  
Fig. 4. Quantitative analysis of lung tissue density changes measured by cone beam 
computed tomography (CBCT) longitudinally for 26 weeks after irradiation. Mice were 
irradiated with a total dose of 20 Gy single fraction in combination with drug vehicle (Panel 
A) or AZD6738 (25 mg/kg per day, Panel C), and with three fractions of 6.67 Gy in 
combination with drug vehicle (Panel B) or AZD6738 (Panel D). Data is presented as the 
difference between the average CT number of the irradiated lung and the average CT number 
in air. Data is presented as raw numbers at all time-points. Probability values were classified 
as *** (p < 0. 005), ** (p < 0. 05) and * (p < 0.1). 
  
Fig. 5. Histological staining and quantification of radiation induced pulmonary fibrosis. 
Stained lungs were electronically scanned and five images scored from the upper region of 
the left lobe. Pulmonary fibrosis was scored using the modified Ashcroft scale (0-8) at 10 x 
magnification by independent and blind observers. Mice were irradiated with a total dose of 
20 Gy single fraction in combination with drug vehicle (Panel A) or with AZD6738 (25 
mg/kg per day, Panel C), and with three fractions of 6.67 Gy in combination with drug 
vehicle (Panel B) or with AZD6738 (Panel D). Data is presented as the fibrosis score ± SEM. 
A representative image from each of the experimental groups is inset in each panel. 
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tumour doubling time (days) 
H460 
tumour quadrupling time 
(days) 
1. Vehicle 38 ± 5.12 
 
3 ± 2.53 
2. Vehicle + 12 Gy 73 ± 5.94 
(cf. group 1, p = 0.004) 
 
25 ± 5.01 
(cf. group 1, p = 0.002) 
 
3. Vehicle + 3 x 4 Gy 80 ± 8.34 
(cf. group 1, p = 0.003) 
(cf. group 2, p =0.016 ) 
40 ± 3.24 
(cf. group 1, p = 0.002) 
(cf. group 2, p = 0.013) 
4. AZD6738 49 ± 3.89  
(cf. group 1, p = 0.380) 
(cf. group 2, p = 0.035) 
(cf. group 3 p =0.103 )   
19 ± 2.53 
(cf. group 1, p = 0.039) 
(cf. group 2, p = 0.165) 
(cf. group 3 p =0.062 )   
5. AZD6738 + 12 Gy 77 ± 7.16  
(cf. group 2, p = 0.005) 
 
52 ± 6.07 
(cf. group 2, p = 0.019) 
 
6. AZD 6738 + 3 x 4 Gy 90 ± 5.12 
(cf. group 3, p = 0.030) 
63 ± 2.18 
(cf. group 3, p = 0.033) 
 
Table 1 
Summary of tumour growth delay parameters with uncertainties for NSCLC cell line derived 
xenografts (CDXs) following treatment with AZD6738 and in combination with single 
fraction and fractionated radiotherapy exposures. Statistical comparisons across different 
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